Patent application number | Description | Published |
20100050086 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 02-25-2010 |
20100050087 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 02-25-2010 |
20100050117 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 02-25-2010 |
20100050123 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 02-25-2010 |
20100058193 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 03-04-2010 |
20140082510 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 03-20-2014 |
20140317520 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 10-23-2014 |
20150072644 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 03-12-2015 |
20150220220 | PREFERRED CONTACT GROUP CENTRIC INTERFACE - A preferred contact group centric interface for a communication device can be used to facilitate communications by a user. The user interface can be arranged to activate from a user's “home page” on the display, from an idle screen that is accessed after a timeout period expires, or any other appropriate mechanism that activates the preferred contact group centric experience. A user selects the preferred contact group from among an array of the user's contacts. Once the contact group is configured, a minimal number of navigation/selection features is necessary to activate any number of communication modes available to the contacts. The contact group is configured such that simple and quick navigation between the contact members is achieved. The contact group can be presented in 2D and 3D arrangements, in any number of list or geometric configurations. A pricing plan can optionally be tied to each member of the contact group. | 08-06-2015 |
Patent application number | Description | Published |
20140303444 | BUTTON PORT - The present disclosure relates to a surgical apparatus for positioning within an incision in tissue. In one aspect of the present disclosure, the surgical access apparatus includes an elongated seal member configured to removably receive at least one surgical object, and a deployment member. In another of the present disclosure, the surgical access apparatus includes a housing configured to removably receive at least one surgical object, an elongated member, and at least one filament. A method of percutaneously accessing an underlying surgical work site using the surgical apparatus is also disclosed. | 10-09-2014 |
20150038795 | SINGLE PORT DEVICE WITH MULTI-LUMEN CAP - A surgical access apparatus includes an access member defining a longitudinal axis and having a longitudinal passageway for reception and passage of a surgical object and an access housing mountable to the access member. The access housing includes a diaphragm mounted thereto. The diaphragm is adapted for rotational movement about the longitudinal axis relative to the access housing. The diaphragm defines at least one internal pocket and has a seal assembly disposed within the internal pocket. The seal assembly has an interface seal member adapted for establishing a fluid tight seal about the surgical object. The seal assembly is adapted for selective movement within the pocket about multiple axes in response to manipulation of the surgical object. | 02-05-2015 |
20150182254 | ACCESS ASSEMBLY - An access assembly is provided. The access assembly includes an access member defining a central longitudinal axis and having a longitudinal opening therethrough for reception and passage of surgical instrument, the access member dimensioned for positioning within tissue to provide access to underlying tissue, and first and second seal members mounted to the access member in juxtaposed relation, the first seal member defining an opening therethrough, the second seal member defining an elongated arcuate passage, wherein the first and second seal members are adapted for rotational movement about the central longitudinal axis whereby the opening of the first seal member is axially alignable with the elongated arcuate passage of the second seal member to permit reception and passage of the surgical instrument in substantial sealed relation therewith, the first and second seal members further adapted for relative rotational movement whereby the first seal member is capable of rotating relative to the second seal member during manipulation and traversal of the surgical instrument through the elongated arcuate passage of the second seal member to maintain the substantial sealed relation about the instrument. | 07-02-2015 |
20150223834 | SINGLE PORT DEVICE WITH MULTI-LUMEN CAP - A surgical access apparatus includes an access member defining a longitudinal axis and having a longitudinal passageway for reception and passage of a surgical object and an access housing mountable to the access member. The access housing includes a diaphragm mounted thereto. The diaphragm is adapted for rotational movement about the longitudinal axis relative to the access housing. The diaphragm defines at least one internal pocket and has a seal assembly disposed within the internal pocket. The seal assembly has an interface seal member adapted for establishing a fluid tight seal about the surgical object. The seal assembly is adapted for selective movement within the pocket about multiple axes in response to manipulation of the surgical object. | 08-13-2015 |
20150327864 | BUTTRESS ASSEMBLY FOR USE WITH SURGICAL STAPLING DEVICE - An apparatus for joining two hollow organ sections includes a staple cartridge component, an anvil component, a knife member, a buttress mount and a buttress member. The staple cartridge component includes a plurality of surgical staples in an annular array. The anvil component is movable relative to the staple cartridge component between spaced apart and approximated positions to adjustably clamp tissue. The knife member is movable relative to the staple cartridge component. The buttress mount is concentrically disposed at least partially within the lumen of the knife member. The buttress mount includes a plurality of spokes radially extending outward and a plurality of legs detachably secured with an inner wall of the knife member. The buttress member is secured with the plurality of spokes of the buttress mount. The buttress member is concentrically aligned with the plurality of surgical staples. | 11-19-2015 |
Patent application number | Description | Published |
20110097349 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 04-28-2011 |
20110105464 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-05-2011 |
20110112085 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-12-2011 |
20130129820 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 05-23-2013 |
20140309216 | PHARMACEUTICAL COMPOUNDS - Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 10-16-2014 |
Patent application number | Description | Published |
20120033694 | BROADENING OF RARE EARTH ION EMISSION BANDWIDTH IN PHOSPHATE BASED LASER GLASSES - Disclosed are the use of phosphate-based glasses as a solid state laser gain medium, in particular, the invention relates to broadening the emission bandwidth of rare earth ions used as lasing ions in a phosphate-based glass composition, where the broadening of the emission bandwidth is believed to be achieved by the hybridization of the glass network. | 02-09-2012 |
20130017387 | CHEMICALLY DURABLE POROUS GLASS WITH ENHANCED ALKALINE RESISTANCEAANM JAMES, III; William H.AACI Clarks SummitAAST PAAACO USAAGP JAMES, III; William H. Clarks Summit PA USAANM Pucilowski; SallyAACI DuryeaAAST PAAACO USAAGP Pucilowski; Sally Duryea PA USAANM Urruti; Eric H.AACI DuryeaAAST PAAACO USAAGP Urruti; Eric H. Duryea PA USAANM Bockmeyer; MatthiasAACI MainzAACO DEAAGP Bockmeyer; Matthias Mainz DE - Disclosed are a phase separable glass compositions used to produce chemically durable porous glass, e.g., porous glass powder, and the application of a sol gel coating to the glass to enhance chemical durability of the glass in alkaline solutions, and to the use of the glass, e.g., glass powder, as substrates for separation technology where harsh alkaline environments (pH≧12 e.g., pH 12-14) are routinely prevalent. | 01-17-2013 |
20130344312 | SILICA AND FLUORIDE DOPED HEAVY METAL OXIDE GLASSES FOR VISIBLE TO MID-WAVE INFRARED RADIATION TRANSMITTING OPTICS AND PREPARATION THEREOF - Disclosed are silica and fluoride doped lead-bismuth-gallium heavy metal oxide glasses for visible to mid-wave Infrared Radiation transmitting optics and preparation thereof. | 12-26-2013 |
20140146839 | TUNING RARE EARTH ION EMISSION WAVELENGTH IN PHOSPHATE BASED GLASSES USING CERIUM OXIDE - The invention relates to a Nd-doped (and/or Yb-doped and/or Er-doped) phosphate laser glass having a peak emission wavelength that is shorter than 1054 nm. Cerium oxide (CeO | 05-29-2014 |
20140146840 | BROADENING THE RARE EARTH ION EMISSION BANDWIDTH, INCREASING EMISSION CROSS SECTION, AND OR SHIFTING PEAK EMISSION WAVELENGTH IN ND DOPED ALUMINATE OR SILICATE GLASSES - The invention relates to a Nd-doped, aluminate-based or silicate-based, laser glass having a peak emission wavelength that is longer than 1059.7 nm, an emission cross section (σ | 05-29-2014 |
20140146841 | ULTRA-BROAD BANDWIDTH LASER GLASSES FOR SHORT-PULSE AND HIGH PEAK POWER LASERS - The invention relates to glasses for use in solid laser applications, particularly short-pulsed, high peak power laser applications. In particular, the invention relates to a method for broadening the emission bandwidth of rare earth ions used as lasing ions in solid laser glass mediums, especially phosphate-based glass compositions, using Nd and Yb as co-dopants. The invention further relates to a laser system using a Nd-doped and Yb-doped phosphate laser glass, and a method of generating a laser beam pulse using such a laser system. | 05-29-2014 |
20140247848 | BROADENING THE RARE EARTH ION EMISSION BANDWIDTH, INCREASING EMISSION CROSS SECTION, AND OR SHIFTING PEAK EMISSION WAVELENGTH IN ND DOPED ALUMINATE OR SILICATE GLASSES - The invention relates to a Nd-doped, aluminate-based or silicate-based, laser glass having a peak emission wavelength that is longer than 1059.7 nm, an emission cross section (σ | 09-04-2014 |
20140270639 | OPTICAL ELEMENT FOR MIE SCATTERING LIGHT FROM AN OPTICAL FIBER - The invention relates to an optical scattering element suitable for dispersing or scattering light transmitted by optical device by Mie scattering. The optical scattering element comprises a phase-separated or porous borosilicate glass having dispersed phase particles with a particle size of 200 to 500 nanometers or pores with a size of 200 to 500 nanometers, at a number density of 10 | 09-18-2014 |
Patent application number | Description | Published |
20090082294 | Diagnosis, prevention and treatment of cancer - Nucleic acid molecules useful in the treatment of cancer are provided. The nucleic acid molecules may include a short interfering ribonucleic acid molecule directed against fer mRNA. A kit for the treatment of cancer including a short interfering ribonucleic acid molecule of the presently described subject matter, as well as a pharmaceutical composition containing a short interfering ribonucleic acid molecule, is also provided. In addition, a method of treating cancer in an individual in which expression of fer in cells or tissues of an individual is inhibited using a short interfering ribonucleic acid molecule is provided. | 03-26-2009 |
20100151452 | Methods and Systems for Searching for Regulators of the Fer Protein and for Monitoring the Effects of the Fer Protein - A method for modulating a Fer mediated pathway in a cell, for monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell is provided. The method includes modulating, monitoring, altering or inhibiting any one or more or of the association of the Fer protein to PP1; the phosphorylation of PP1, the phosphatase activity of PP1, and the tumor suppressive activity of the retinoblastoma protein (RB). In a preferred embodiment, modulating a Fer mediated pathway in a cell, monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell involves administrating to a cell a compound having a molecular weight of up to 1000 Dalton capable of modulating, altering or inhibiting an effect of Fer. Further provided is a method for determining whether a substance is capable of altering or inhibiting an effect of a Fer protein in a cell. The method includes presenting the substance to a first cell expressing an exogenous Fer gene or Fer cDNA; and measuring a rate of proliferation of the cell. A significant difference between the growth rate of the first cell and the growth rate of a second cell not expressing an exogenous Fer gene or Fer cDNA indicates that the substance is capable of altering a fer mediated pathway. | 06-17-2010 |
20110028533 | NOVEL FER -LIKE PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND METHOD FOR ITS USE - Provided is a novel Fer-like protein, referred to as “FerC” (Fer colorectal cancer). FerC is a 47kDa protein having a unique N-terminal sequence and was found to be present in six colon cancer cell-lines and in five hepatocarcinoma (liver cancer) cell-lines, but not in CCD33 normal colon epithelial cells or normal human and mouse fibroblasts. Depletion of FerC impairs cell-cycle progression and induces apoptotic death in treated colon cancer (CC) cells. Also provided are nucleotide sequences that are antisense to at least a portion of the N-terminal sequence, short interfering nucleotides including such an antisense sequence, as well as pharmaceutical compositions containing an antisense sequence. The present pharmaceutical composition may be used in the treatment of cancer, in particular, colorectal cancer and liver cancer. | 02-03-2011 |
20110086861 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided is a pharmaceutical composition including as an active component a compound of formula (I): | 04-14-2011 |
20110306619 | 6-PHENYL-2-[((PIPERIDIN-4-YLMETHYL)-PIPERAZIN-1YL) OR PIPERAZIN 1-YLMETHYL)-PIPERIDIN-1-YL)]-IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES AND THEIR USE - Provided are heterocyclic compounds, their synthesis and pharmaceutical compositions including them for the treatment of disorders, in particular, cancer. | 12-15-2011 |
20130072448 | Drug Combination Comprising A Glycolysis Inhibitor And A Tyrosine Kinase Inhibitor - A drug combination comprising at least one inhibitor of tyrosine kinase and at least one inhibitor of glycolysis. The drug combination may be used in the treatment of proliferative disorders, such as liver or colon cancer. The inhibitor of tyrosine kinase may be an inhibitor of at least one of the tyrosine kinases Fer and FerT. | 03-21-2013 |